Medtronic Q3 Revenue Misses, EPS Guidance Updated

Medtronic reported third-quarter fiscal 2025 revenues of $8.29 billion, a 2.5% year-over-year increase but missing analyst estimates due to a decline in its Medical Surgical division, which saw revenues fall approximately 2%. However, the Cardiovascular and Neuroscience portfolios showed strong growth, with revenues rising around 4% year-over-year. The company's adjusted earnings per share (EPS) were $1.39, surpassing analyst expectations. Despite the revenue miss, Medtronic reaffirmed its FY25 guidance, projecting organic revenue growth of 4.75% to 5% and adjusted EPS between $5.44 and $5.50. Shares of Medtronic fell in pre-market trading, reflecting investor concerns over the sales miss.